In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.
Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.
Zhou Y, Pang L, Ding T, Chen K, Liu J, Wu M, Wang W, Man K.
Cancer Res. 2024 Nov 15;84(22):3834-3847. doi: 10.1158/0008-5472.CAN-24-0220.
Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer.
Qian X, Yang H, Ye Z, Gao B, Qian Z, Ding Y, Mao Z, Du Y, Wang W.
ACS Nano. 2024 Jun 18;18(24):15864-15877. doi: 10.1021/acsnano.4c02947. Epub 2024 Jun 3.
In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma.
Ke J, Liu Y, Liu F, Cai H, Li X, Zhang Z, Wang N, Shao B, Wang Z, Han M, Ji B.
J Control Release. 2024 Aug;372:141-154. doi: 10.1016/j.jconrel.2024.06.030. Epub 2024 Jun 18.
Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling.
Sun X, Cai W, Li H, Gao C, Ma X, Guo Y, Fu D, Xiao D, Zhang Z, Wang Y, Yang S, Feng Y, Zhao T, Hao J.
Gut. 2025 Aug 7;74(9):1437-1451. doi: 10.1136/gutjnl-2024-333638.
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Daneshmand S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, Bögemann M, Simone G, Pieczonka CM, Casco NC, Zainfeld D, Spiegelhalder P, Xylinas E, Cahn D, Lotan Y, Murray KS, Kawahara T, Stromberg K, Martin J, Shukla A, Cutie CJ, Bertzos K, Hampras S, Sweiti H, Necchi A; SunRISe-1 Study.
J Clin Oncol. 2025 Jul 30:JCO2501651. doi: 10.1200/JCO-25-01651. Online ahead of print.
In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.
Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C.
Oncoimmunology. 2018 Mar 19;7(5):e1424673. doi: 10.1080/2162402X.2018.1424673. eCollection 2018.
Electrochemotherapy combined with immunotherapy - a promising potential in the treatment of cancer.
Hadzialjevic B, Omerzel M, Trotovsek B, Cemazar M, Jesenko T, Sersa G, Djokic M.
Front Immunol. 2024 Jan 15;14:1336866. doi: 10.3389/fimmu.2023.1336866. eCollection 2023.
In Situ Nanoparticle Self-Assembly for Combination Delivery of Therapeutics to Non-Small Cell Lung Cancer.
Hatami E, Nagesh PKB, Chauhan N, Jaggi M, Chauhan SC, Yallapu MM.
ACS Appl Bio Mater. 2022 Mar 21;5(3):1104-1119. doi: 10.1021/acsabm.1c01158. Epub 2022 Feb 18.
Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Xia X, Li X, Feng G, Zheng C, Liang H, Zhou G.
Acta Radiol. 2013 Jul;54(6):684-9. doi: 10.1177/0284185113480072. Epub 2013 Apr 30.
Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma.
Tatarova Z, Blumberg DC, Bensen A, Mills GB, Jonas O.
Cells. 2023 Jan 13;12(2):308. doi: 10.3390/cells12020308.
